Insider Selling: Billiontoone (NASDAQ:BLLN) CEO Sells $1,563,197.93 in Stock

Key Points

• CEO Oguzhan Atay sold 16,667 Billiontoone shares at an average price of $93.79, generating approximately $1.56 million. The transaction, conducted under a Rule 10b5-1 plan, reduced his direct ownership by 50%.
• Atay has made several additional sales since August, totaling millions of dollars, while Billiontoone shares recently traded at $97.88. The stock has a one-year range of $61.96 to $150.44 and a market capitalization of approximately $4.62 billion.
• Analysts maintain a generally positive outlook, with seven Buy, three Hold, and one Sell rating, producing a Moderate Buy consensus and an average price target of $126.25.

Billiontoone, Inc. (NASDAQ:BLLN - Get Free Report) CEO Oguzhan Atay sold 16,667 shares of the stock in a transaction on Monday, October 12th. The stock was sold at an average price of $93.79, for a total transaction of $1,563,197.93. Following the completion of the sale, the chief executive officer directly owned 16,667 shares of the company's stock, valued at approximately $1,563,197.93. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oguzhan Atay also recently made the following trade(s):

• On Monday, October 12th, Oguzhan Atay sold 2,667 shares of Billiontoone stock. The shares were sold at an average price of $97.61, for a total transaction of $260,325.87.
• On Monday, September 28th, Oguzhan Atay sold 2,666 shares of Billiontoone stock. The shares were sold at an average price of $120.64, for a total value of $321,626.24.
• On Monday, September 28th, Oguzhan Atay sold 8,333 shares of Billiontoone stock. The stock was sold at an average price of $120.64, for a total value of $1,005,293.12.
• On Monday, September 14th, Oguzhan Atay sold 5,332 shares of Billiontoone stock. The stock was sold at an average price of $98.00, for a total value of $522,536.00.
• On Monday, September 14th, Oguzhan Atay sold 24,999 shares of Billiontoone stock. The stock was sold at an average price of $100.32, for a total value of $2,507,899.68.
• On Monday, August 3rd, Oguzhan Atay sold 12,500 shares of Billiontoone stock. The shares were sold at an average price of $137.37, for a total value of $1,717,125.00.
• On Monday, August 3rd, Oguzhan Atay sold 32,500 shares of Billiontoone stock. The shares were sold at an average price of $136.95, for a total value of $4,450,875.00.

Billiontoone Price Performance

NASDAQ BLLN traded up $3.44 during trading hours on Wednesday, reaching $97.88. The company's stock had a trading volume of 424,883 shares, compared to its average volume of 552,974. The firm's 50-day moving average price is $101.72 and its 200-day moving average price is $101.18. The company has a quick ratio of 11.31, a current ratio of 11.69 and a debt-to-equity ratio of 0.17. Billiontoone, Inc. has a 1 year low of $61.96 and a 1 year high of $150.44. The company has a market capitalization of $4.62 billion and a price-to-earnings ratio of 139.83.

Billiontoone (NASDAQ:BLLN - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.15 earnings per share for the quarter, hitting the consensus estimate of $0.15. Billiontoone had a return on equity of 9.96% and a net margin of 8.04%. The business had revenue of $109.45 million during the quarter. On average, equities research analysts predict that Billiontoone, Inc. will post 0.83 EPS for the current fiscal year.

Hedge Funds Weigh In On Billiontoone

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Toth Financial Advisory Corp lifted its holdings in shares of Billiontoone by 60.0% in the 3rd quarter. Toth Financial Advisory Corp now owns 800 shares of the company's stock valued at $85,000 after acquiring an additional 300 shares during the last quarter. Family Legacy Financial Solutions LLC purchased a new position in shares of Billiontoone in the 3rd quarter worth approximately $53,000. MCF Advisors LLC increased its position in shares of Billiontoone by 330.8% during the 2nd quarter. MCF Advisors LLC now owns 448 shares of the company's stock valued at $54,000 after purchasing an additional 344 shares during the last quarter. Integrated Wealth Concepts LLC bought a new position in shares of Billiontoone during the 2nd quarter valued at approximately $29,000. Finally, Thrive Wealth Management LLC purchased a new stake in Billiontoone during the 2nd quarter valued at $240,000.

Analysts Set New Price Targets

BLLN has been the topic of several research analyst reports. JPMorgan Chase & Co. decreased their price target on shares of Billiontoone from $145.00 to $130.00 and set an "overweight" rating on the stock in a research note on Thursday, August 6th. Guggenheim raised their price objective on Billiontoone from $125.00 to $128.00 and gave the company a "buy" rating in a research report on Thursday, October 1st. Weiss Ratings cut Billiontoone from a "sell (d+)" rating to a "sell (d)" rating in a report on Thursday, October 8th. Wall Street Zen downgraded Billiontoone from a "buy" rating to a "hold" rating in a research report on Saturday, August 8th. Finally, Zacks Research upgraded Billiontoone from a "strong sell" rating to a "hold" rating in a research report on Friday, October 2nd. Seven investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Billiontoone presently has an average rating of "Moderate Buy" and a consensus price target of $126.25.

About Billiontoone

BillionToOne, Inc NASDAQ: BLLN is a molecular diagnostics company that develops blood-based genetic tests designed to provide more information from small amounts of cell-free DNA. The company's platform uses proprietary molecular counting technology to improve the sensitivity and accuracy of diagnostic testing.

BillionToOne's primary business is reproductive health testing. Its UNITY portfolio is designed to support prenatal screening, including testing for chromosomal conditions and single-gene disorders, and is intended to provide physicians and expectant parents with information from a maternal blood sample.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.